Neovacs SA (FR:ALNEV) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Neovacs has announced that their mRNA vaccine has shown higher efficacy in treating allergies compared to their protein vaccine in a preclinical trial with non-human primates. The company’s mRNA technology has prompted them to extend the study for long-term efficacy and prepare for a Phase I/IIa human trial. Neovacs combines R&D and investment activities, focusing on innovative immunotherapies for autoimmune diseases and allergies.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.